quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·23d
PRRelease
Indivior Pharmaceuticals Inc. logo

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

INDV· Indivior Pharmaceuticals Inc.
Health Care
Original source

Companies

  • INDV
    Indivior Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Aug 6UpdateH.C. Wainwright$27.00
  • Jul 22UpdateJefferies$20.00
  • Jan 28UpdateRodman & Renshaw$16.00
  • Jul 23UpdatePiper Sandler$22.00
  • Apr 3UpdateCraig Hallum$37.00
  • Jul 13UpdateNorthland Capital$35.00

Related

  • PR7d
    Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
  • PR14d
    Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
  • SEC27d
    SEC Form DEFA14A filed by Indivior Pharmaceuticals Inc.
  • SEC27d
    SEC Form DEF 14A filed by Indivior Pharmaceuticals Inc.
  • SEC31d
    SEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.
  • INSIDER37d
    Chief Financial Officer Preblick Ryan converted options into 6,302 shares and covered exercise/tax liability with 2,843 shares, increasing direct ownership by 1% to 320,751 units (SEC Form 4)
  • SEC37d
    Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
  • PR37d
    National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022